MAPT and Alzheimer disease: Our results demonstrate that CK2 inhibition has a neuroprotective impact in the in vitro AD model, as evidenced by decreased levels of Aβ1–42 and phospho-Tau (T181), along with enhanced ADAM10 gene expression and suppressed BACE1 gene expression.